Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LINDSAY S ACKERMAN

Allopathic & Osteopathic Physicians Dermatology

NPI
1609900299
CMS profile
27818
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$130,412.01

187 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LINDSAY S ACKERMAN

NPI 1609900299 · CMS profile ID 27818

Allopathic & Osteopathic Physicians / Dermatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LINDSAY S ACKERMAN, NPI 1609900299, CMS profile ID 27818, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–187 of 187 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1609900299?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

187 matching records · $130,412.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 187 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–187 of 187.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $2,275.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779449 CMS
Helsinn Therapeutics (U.S.), Inc. $2,667.5003/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655943917 CMS
AbbVie, Inc. $110.0003/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779453 CMS
AbbVie, Inc. $345.2403/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779461 CMS
AbbVie, Inc. $5,200.0003/19/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779485 CMS
Celgene Corporation $2.8203/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672759795 CMS
AbbVie, Inc. $5.9703/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779451 CMS
Sun Pharmaceutical Industries Inc. $6,000.0003/11/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590691 CMS
Sun Pharmaceutical Industries Inc. $1,155.0903/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590693 CMS
Sun Pharmaceutical Industries Inc. $246.3303/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590695 CMS
Sun Pharmaceutical Industries Inc. $70.3103/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590697 CMS
Biofrontera Inc. $16.4603/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687913939 CMS
AbbVie, Inc. $4.1303/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779515 CMS
SANOFI-AVENTIS U.S. LLC $19.5003/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693964765 CMS
Janssen Biotech, Inc. $67.3803/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658292601 CMS
Johnson & Johnson Health Care Systems Inc. $60.0503/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 644342574 CMS
Lilly USA, LLC $14.5002/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657975891 CMS
Genentech USA, Inc. $19.4902/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681270531 CMS
Celgene Corporation $2.4702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672759706 CMS
AbbVie, Inc. $1,300.0001/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779445 CMS
AbbVie, Inc. $24.3001/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779447 CMS
Celgene Corporation $5.3401/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672714657 CMS
Sun Pharmaceutical Industries Inc. $6,000.0001/23/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590673 CMS
Sun Pharmaceutical Industries Inc. $710.2801/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590675 CMS
Sun Pharmaceutical Industries Inc. $215.8401/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590677 CMS
Sun Pharmaceutical Industries Inc. $35.5001/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590679 CMS
Sun Pharmaceutical Industries Inc. $23.3301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590681 CMS
Sun Pharmaceutical Industries Inc. $8,800.0001/23/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590683 CMS
Sun Pharmaceutical Industries Inc. $25.0001/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590685 CMS
Sun Pharmaceutical Industries Inc. $23.3201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590687 CMS
Sun Pharmaceutical Industries Inc. $12.2301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590689 CMS
Sun Pharmaceutical Industries Inc. $35.5001/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704590713 CMS
Genentech USA, Inc. $19.7101/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681151239 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.6701/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684565103 CMS
AbbVie, Inc. $54.0001/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779583 CMS
AbbVie, Inc. $7,800.0001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779585 CMS
AbbVie, Inc. $30.8401/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647779587 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $130,412.01 187
PY2020 $118,991.70 127
PY2021 $103,822.74 125
PY2022 $269,706.07 255
PY2023 $283,228.42 316
PY2024 $313,763.22 410
PY2025 $360,526.07 435

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,128,315.86 303
PY2024 Recipient $9,104.58 2
PY2024 Principal investigator $1,402,000.34 351
PY2023 Recipient $1,216.57 9
PY2023 Principal investigator $1,090,856.71 307
PY2022 Principal investigator $969,713.61 162
PY2021 Principal investigator $922,895.00 86
PY2020 Recipient $43.62 1
PY2020 Principal investigator $257,398.28 37
PY2019 Principal investigator $53,058.99 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

303 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $4,380.00 12/31/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202535219
Principal investigator 1 ABBVIE INC. $6,010.00 12/30/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202532162
Principal investigator 1 ABBVIE INC. $7,020.00 12/30/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202532172
Principal investigator 1 Incyte Corporation $1,500.00 12/24/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553650
Principal investigator 1 Incyte Corporation $1,500.00 12/24/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553656
Principal investigator 1 Incyte Corporation $3,500.00 12/24/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553728
Principal investigator 1 Incyte Corporation $1,000.00 12/24/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553794
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 12/22/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156739
Principal investigator 1 Incyte Corporation $1,736.00 12/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553686
Principal investigator 1 Incyte Corporation $1,510.00 12/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553692
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553710
Principal investigator 1 Incyte Corporation $47.00 12/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553716
Principal investigator 1 Incyte Corporation $1,659.00 12/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553752
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 12/17/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760141
Principal investigator 1 Boehringer Ingelheim International GmbH $7.20 12/17/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760143
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 12/17/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760145
Principal investigator 1 Boehringer Ingelheim International GmbH $70.38 12/17/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760147
Principal investigator 1 Boehringer Ingelheim International GmbH $10.50 12/17/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760149
Principal investigator 1 Incyte Corporation $10,772.00 12/08/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553722
Principal investigator 1 Incyte Corporation $2,250.00 12/08/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553740
Principal investigator 1 ABBVIE INC. $7,769.00 12/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527224
Principal investigator 1 ABBVIE INC. $2,500.00 12/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202527430
Principal investigator 1 ABBVIE INC. $23,038.40 12/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527432
Principal investigator 1 Incyte Corporation $757.80 12/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592819
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553626
Principal investigator 1 Incyte Corporation $33.18 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553632
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553638
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553644
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553662
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553668
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553674
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553680
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553734
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553770
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553806
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553811
Principal investigator 1 Incyte Corporation $1,373.40 11/24/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553698
Principal investigator 1 Incyte Corporation $79.00 11/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553704
Principal investigator 1 Incyte Corporation $2,426.00 11/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553776
Principal investigator 1 Incyte Corporation $2,426.00 11/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553782
Principal investigator 1 Incyte Corporation $9,000.00 11/10/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553746
Principal investigator 1 Incyte Corporation $3,000.00 11/10/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240553800
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,121.87 11/10/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190309742
Principal investigator 1 ABBVIE INC. $650.75 11/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202521669
Principal investigator 1 ABBVIE INC. $7,958.60 11/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521671
Principal investigator 1 ARGENX US, INC. $750.00 11/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157626
Principal investigator 1 ARGENX US, INC. $2,000.00 11/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157630
Principal investigator 1 ARGENX US, INC. $1,168.76 11/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157647
Principal investigator 1 Incyte Corporation $6,500.00 10/29/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592811
Principal investigator 1 Incyte Corporation $1,965.00 10/29/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592815
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760123
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760125
Principal investigator 1 Boehringer Ingelheim International GmbH $109.25 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760127
Principal investigator 1 Boehringer Ingelheim International GmbH $50.70 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760129
Principal investigator 1 Boehringer Ingelheim International GmbH $50.70 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760131
Principal investigator 1 Boehringer Ingelheim International GmbH $50.70 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760133
Principal investigator 1 Boehringer Ingelheim International GmbH $50.70 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760135
Principal investigator 1 Boehringer Ingelheim International GmbH $117.30 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760137
Principal investigator 1 Boehringer Ingelheim International GmbH $17.50 10/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760139
Principal investigator 1 ARGENX US, INC. $3,171.15 10/24/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157658
Principal investigator 1 Incyte Corporation $11,323.50 10/22/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553788
Principal investigator 1 LEO Pharma AS $411.00 10/20/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251993935
Principal investigator 1 ARGENX US, INC. $2,750.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157634
Principal investigator 1 ARGENX US, INC. $1,500.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157638
Principal investigator 1 ARGENX US, INC. $1,100.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157643
Principal investigator 1 ARGENX US, INC. $1,092.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157651
Principal investigator 1 ARGENX US, INC. $2,500.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157655
Principal investigator 1 ARGENX US, INC. $1,863.00 10/17/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157662
Principal investigator 1 ABBVIE INC. $650.75 10/09/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202514735
Principal investigator 1 ABBVIE INC. $14,295.70 10/09/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514737
Principal investigator 1 ABBVIE INC. $5,484.00 10/09/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202514869
Principal investigator 1 Eli Lilly and Company $14,000.00 10/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187891296
Principal investigator 1 Eli Lilly and Company $14,000.00 10/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187891298
Principal investigator 1 Incyte Corporation $2,288.00 10/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553758
Principal investigator 1 Incyte Corporation $2,288.00 10/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553764
Principal investigator 1 Incyte Corporation $2,421.00 10/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553817
Principal investigator 1 Incyte Corporation $2,421.00 10/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553824
Principal investigator 1 Incyte Corporation $542.30 10/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,147.74 10/01/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286121
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,790.79 10/01/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286141
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31.11 09/19/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220813193
Principal investigator 1 ABBVIE INC. $13,461.40 09/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509510
Principal investigator 1 ABBVIE INC. $1,386.50 09/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202509620
Principal investigator 1 Incyte Corporation $1,132.20 09/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592807
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,000.00 09/04/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434721
Principal investigator 1 ABBVIE INC. $1,406.70 09/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507927
Principal investigator 1 ABBVIE INC. $22,774.00 09/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508028
Principal investigator 1 Incyte Corporation $11.66 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553532
Principal investigator 1 Incyte Corporation $135.40 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553562
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553579
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553584
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553588
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553593
Principal investigator 1 Incyte Corporation $59.13 09/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553608
Principal investigator 1 ARGENX US, INC. $1,928.52 08/27/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157621
Principal investigator 1 Incyte Corporation $1,183.30 08/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553523
Principal investigator 1 Incyte Corporation $375.00 08/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553528
Principal investigator 1 Incyte Corporation $1,526.00 08/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553614
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,723.28 08/15/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284351
Principal investigator 1 ABBVIE INC. $1,386.50 08/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202503447
Principal investigator 1 ABBVIE INC. $36,327.20 08/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503551
Principal investigator 1 ABBVIE INC. $17,411.00 08/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502110
Principal investigator 1 Incyte Corporation $2,199.60 08/04/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553537
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553555
Principal investigator 1 Incyte Corporation $98.72 08/04/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553567
Principal investigator 1 Incyte Corporation $80.15 08/04/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553574
Principal investigator 1 Incyte Corporation $32.36 08/04/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553620
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,549.77 08/01/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283391
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 07/23/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226094014
Principal investigator 1 Incyte Corporation $2,291.40 07/22/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592801
Principal investigator 1 Incyte Corporation $1,131.30 07/18/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553543
Principal investigator 1 Incyte Corporation $2,421.00 07/18/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553550
Principal investigator 1 SANOFI US SERVICES INC. $938.25 07/11/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226094019
Principal investigator 1 Incyte Corporation $2,264.40 07/10/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592804
Principal investigator 1 Incyte Corporation $1,528.20 07/09/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553599
Principal investigator 1 LEO Pharma AS $1,000.00 07/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251993523
Principal investigator 1 ABBVIE INC. $17,928.00 07/02/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495837
Principal investigator 1 ABBVIE INC. $1,406.70 07/02/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495839
Principal investigator 1 ABBVIE INC. $15,181.20 07/02/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495873
Principal investigator 1 UCB SA $70.00 06/26/2025 Non-covered Recipient Entity
Perseverance Research Center
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246658184
Principal investigator 1 Incyte Corporation $375.00 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553282
Principal investigator 1 Incyte Corporation $976.50 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553288
Principal investigator 1 Incyte Corporation $1,649.00 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553294
Principal investigator 1 Incyte Corporation $1,526.00 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553464
Principal investigator 1 Incyte Corporation $1,526.00 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553470
Principal investigator 1 Incyte Corporation $180.00 06/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553298
Principal investigator 1 Incyte Corporation $2,503.71 06/13/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553210
Principal investigator 1 Incyte Corporation $164.56 06/13/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553455
Principal investigator 1 Incyte Corporation $2,193.00 06/11/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553336
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,937.28 06/11/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281078
Principal investigator 1 Incyte Corporation $1,528.20 06/06/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553322
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,000.00 06/05/2025 Non-covered Recipient Entity
Southwest Skin Specialists dba Medical Dermatology Specialists
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220814617
Principal investigator 1 Amgen Inc. $14,392.00 06/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,446.56 06/04/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280714
Principal investigator 1 ABBVIE INC. $1,840.73 06/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202488179
Principal investigator 1 ABBVIE INC. $4,213.50 06/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202488181
Principal investigator 1 ABBVIE INC. $26,433.00 06/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488183
Principal investigator 1 ABBVIE INC. $6,274.90 06/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202488185
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553369
Principal investigator 1 Incyte Corporation $0.31 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553396
Principal investigator 1 Incyte Corporation $2.43 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553402
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553409
Principal investigator 1 Incyte Corporation $8.24 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553415
Principal investigator 1 Incyte Corporation $11.45 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553421
Principal investigator 1 Incyte Corporation $11.33 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553426
Principal investigator 1 Incyte Corporation $91.60 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553432
Principal investigator 1 Incyte Corporation $24.68 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553482
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553514
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553519
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Southwest Skin Specialists
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228763770
Principal investigator 1 ABBVIE INC. $1,500.00 05/29/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202486871
Principal investigator 1 Eli Lilly and Company $2,471.11 05/27/2025 Non-covered Recipient Entity
ADVANCED MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187875715
Principal investigator 1 ARGENX US, INC. $1,500.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157587
Principal investigator 1 ARGENX US, INC. $750.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157590
Principal investigator 1 ARGENX US, INC. $1,100.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157594
Principal investigator 1 ARGENX US, INC. $3,250.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157599
Principal investigator 1 ARGENX US, INC. $4,031.84 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157607
Principal investigator 1 ARGENX US, INC. $2,184.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157611
Principal investigator 1 ARGENX US, INC. $2,000.00 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157615
Principal investigator 1 ARGENX US, INC. $147.15 05/21/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157618
Principal investigator 1 Incyte Corporation $1,526.00 05/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553227
Principal investigator 1 Incyte Corporation $1,568.50 05/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553239
Principal investigator 1 Incyte Corporation $1,526.00 05/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553486
Principal investigator 1 Incyte Corporation $1,526.00 05/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553492
Principal investigator 1 Incyte Corporation $1,526.00 05/21/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553497
Principal investigator 1 SANOFI US SERVICES INC. $1,025.00 05/19/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156460
Principal investigator 1 Incyte Corporation $1,132.20 05/15/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS PHOENIX BILTMORE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240592798
Principal investigator 1 ABBVIE INC. $18,068.95 05/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482771
Principal investigator 1 Incyte Corporation $2,444.00 05/07/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553251
Principal investigator 1 Incyte Corporation $1,293.70 05/07/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553476
Principal investigator 1 ABBVIE INC. $14,859.00 05/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481451
Principal investigator 1 Incyte Corporation $57.25 05/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553197
Principal investigator 1 Incyte Corporation $2,288.00 05/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553246
Principal investigator 1 Incyte Corporation $1,649.00 05/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553257
Principal investigator 1 Incyte Corporation $1,620.30 05/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553263
Principal investigator 1 Incyte Corporation $1,649.00 05/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553507
Principal investigator 1 ARGENX US, INC. $3,171.15 05/01/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157602
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $31.11 04/15/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220813191
Principal investigator 1 SANOFI US SERVICES INC. $938.25 04/11/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226093991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,755.00 04/11/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277836
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,056.66 04/11/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278048
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,236.18 04/09/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235993559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,687.56 04/09/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277754
Principal investigator 1 Incyte Corporation $1,528.20 04/07/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553233
Principal investigator 1 Incyte Corporation $1,929.60 04/07/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553438
Principal investigator 1 SANOFI US SERVICES INC. $1,025.00 04/07/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156400
Principal investigator 1 ABBVIE INC. $18,911.00 04/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202473841
Principal investigator 1 ABBVIE INC. $24,046.80 04/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202473846
Principal investigator 1 ABBVIE INC. $2,062.10 04/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202474309
Principal investigator 1 Incyte Corporation $954.50 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553203
Principal investigator 1 Incyte Corporation $1,526.00 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553217
Principal investigator 1 Incyte Corporation $375.00 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553223
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553268
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553276
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553304
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553311
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553315
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553328
Principal investigator 1 Incyte Corporation $58.30 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553343
Principal investigator 1 Incyte Corporation $132.50 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553349
Principal investigator 1 Incyte Corporation $201.40 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553355
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553361
Principal investigator 1 Incyte Corporation $397.50 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553378
Principal investigator 1 Incyte Corporation $376.30 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553385
Principal investigator 1 Incyte Corporation $47.70 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553391
Principal investigator 1 Incyte Corporation $2,288.00 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553443
Principal investigator 1 Incyte Corporation $328.60 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553450
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553501
Principal investigator 1 Eli Lilly and Company $20,564.00 03/18/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187888916
Principal investigator 1 ABBVIE INC. $5,931.90 03/13/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202463282
Principal investigator 1 Incyte Corporation $1,114.00 03/12/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552961
Principal investigator 1 Incyte Corporation $1,698.00 03/12/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553001
Principal investigator 1 Incyte Corporation $2,444.00 03/12/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553163
Principal investigator 1 SANOFI US SERVICES INC. $3,190.80 03/10/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156404
Principal investigator 1 ABBVIE INC. $22,634.60 03/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460400
Principal investigator 1 ABBVIE INC. $1,489.06 03/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460404
Principal investigator 1 ABBVIE INC. $4,672.50 03/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202460408
Principal investigator 1 ABBVIE INC. $1,360.50 03/06/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202457236
Principal investigator 1 ABBVIE INC. $9,527.00 03/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457481
Principal investigator 1 Incyte Corporation $1,373.40 03/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553008
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553094
Principal investigator 1 Incyte Corporation $4.86 03/03/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553100
Principal investigator 1 Janssen Research & Development, LLC $2,625.00 03/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175423065
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,666.97 02/26/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275659
Principal investigator 1 Incyte Corporation $1,358.40 02/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552950
Principal investigator 1 Incyte Corporation $1,698.00 02/19/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552955
Principal investigator 1 SANOFI US SERVICES INC. $1,239.00 02/18/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156392
Principal investigator 1 ARGENX US, INC. $1,433.70 02/12/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157666
Principal investigator 1 Janssen Research & Development, LLC $2,408.00 02/07/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175423060
Principal investigator 1 ABBVIE INC. $24,512.06 02/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449238
Principal investigator 1 Incyte Corporation $1.96 02/06/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553157
Principal investigator 1 ABBVIE INC. $268.25 02/05/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202445452
Principal investigator 1 ABBVIE INC. $19,221.00 02/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202445633
Principal investigator 1 Eli Lilly and Company $57,341.00 02/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187890918
Principal investigator 1 Incyte Corporation $1,894.00 02/05/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240552945
Principal investigator 1 Incyte Corporation $1,515.20 02/05/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240553151
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,230.41 02/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274697
Principal investigator 1 Amgen Inc. $6,560.00 01/30/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246644175
Principal investigator 1 Eli Lilly and Company $82,990.00 01/28/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187889852
Principal investigator 1 Amgen Inc. $12,681.92 01/27/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246644172
Principal investigator 1 Boehringer Ingelheim International GmbH $6.64 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760095
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760097
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760099
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760101
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760103
Principal investigator 1 Boehringer Ingelheim International GmbH $87.40 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760105
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760107
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760109
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760111
Principal investigator 1 Boehringer Ingelheim International GmbH $30.42 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760113
Principal investigator 1 Boehringer Ingelheim International GmbH $19.54 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760115
Principal investigator 1 Boehringer Ingelheim International GmbH $23.84 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760117
Principal investigator 1 Boehringer Ingelheim International GmbH $62.56 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760119
Principal investigator 1 Boehringer Ingelheim International GmbH $11.00 01/27/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760121
Principal investigator 1 Incyte Corporation $2,288.00 01/27/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552968
Principal investigator 1 Incyte Corporation $839.40 01/27/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552974
Principal investigator 1 Incyte Corporation $1,526.00 01/27/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552980
Principal investigator 1 Incyte Corporation $1,526.00 01/27/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,723.28 01/22/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274379
Principal investigator 1 SANOFI US SERVICES INC. $2,836.00 01/21/2025 Non-covered Recipient Entity
Oliver Street Dermatology Managemen U S Dermatology Partners Southwest Skin Specialists Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226156377
Principal investigator 1 Incyte Corporation $989.80 01/17/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552931
Principal investigator 1 Incyte Corporation $1,698.00 01/17/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552936
Principal investigator 1 Incyte Corporation $1,843.00 01/17/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553137
Principal investigator 1 Incyte Corporation $1,843.00 01/17/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553143
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,706.50 01/16/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235993561
Principal investigator 1 Boehringer Ingelheim International GmbH $7,440.40 01/15/2025 Non-covered Recipient Entity
US Dermatology Partners-Phoenix
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy No dispute reported 06/30/2026 1220760093
Principal investigator 1 Eli Lilly and Company $3,603.29 01/15/2025 Non-covered Recipient Entity
ADVANCED MEDICAL RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187874129
Principal investigator 1 Incyte Corporation $1,526.00 01/15/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552904
Principal investigator 1 Incyte Corporation $1,649.00 01/15/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552921
Principal investigator 1 Incyte Corporation $1,708.80 01/15/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552924
Principal investigator 1 Incyte Corporation $1,526.00 01/15/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553167
Principal investigator 1 SANOFI US SERVICES INC. $1,876.50 01/15/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226093979
Principal investigator 1 SANOFI US SERVICES INC. $210.60 01/15/2025 Non-covered Recipient Entity
Southwest Skin Specialists Llc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226093986
Principal investigator 1 ARGENX US, INC. $9,115.57 01/10/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid No dispute reported 06/30/2026 1237157671
Principal investigator 1 Incyte Corporation $1,515.20 01/10/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240552909
Principal investigator 1 Incyte Corporation $1,894.00 01/10/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240552915
Principal investigator 1 UCB SA $63,375.00 01/03/2025 Non-covered Recipient Entity
US DERMATOLOGY PARTNERS PHOENIX 7TH ST
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246656244
Principal investigator 1 ABBVIE INC. $1,360.50 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PC
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202435376
Principal investigator 1 ABBVIE INC. $601.43 01/02/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202435653
Principal investigator 1 Incyte Corporation $19.44 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552986
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552992
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240552996
Principal investigator 1 Incyte Corporation $64.72 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553014
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553024
Principal investigator 1 Incyte Corporation $114.50 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553030
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553035
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553042
Principal investigator 1 Incyte Corporation $64.72 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553048
Principal investigator 1 Incyte Corporation $14.84 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553053
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553061
Principal investigator 1 Incyte Corporation $20.60 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553066
Principal investigator 1 Incyte Corporation $28.84 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553073
Principal investigator 1 Incyte Corporation $74.04 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553078
Principal investigator 1 Incyte Corporation $48.54 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553083
Principal investigator 1 Incyte Corporation $24.68 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553088
Principal investigator 1 Incyte Corporation $91.60 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553107
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553112
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553118
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553126
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553132
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553180
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553186
Principal investigator 1 Incyte Corporation $41.10 01/02/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS PHOENIX
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240553193